Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H33N3O2.ClH |
| Molecular Weight | 419.988 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=CC2=C1N(CC3CCCCC3)C=C2C(=O)N4CCN(C)[C@@H](C)C4
InChI
InChIKey=HKDNZWSVLVVYEP-LMOVPXPDSA-N
InChI=1S/C23H33N3O2.ClH/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3;/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3;1H/t17-;/m0./s1
DescriptionCurator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00782951 | https://www.ncbi.nlm.nih.gov/pubmed/18635703 | http://pubs.rsc.org/en/content/articlehtml/2010/md/c0md00022a
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00782951 | https://www.ncbi.nlm.nih.gov/pubmed/18635703 | http://pubs.rsc.org/en/content/articlehtml/2010/md/c0md00022a
ORG-28611 (SCH-900,111) is a potent cannabinoid receptor full agonist, developed by Organon International for treatment pain. In preclinical studies, Org 28611 exhibited high affinity for both CB1 and CB2 cannabinoid receptors, as determined by radioligand competition binding assays and rapidly metabolized by mouse and human hepatic microsomes and showed higher total levels in the brain compared to plasma. In clinical trials, Org 28611 does not provide enough sedation for outpatient surgical procedures, does not induce anterograde amnesia and causes undesirable subjective effects at higher doses. However, bolus doses up to 3 μ/kg (with maximum initial plasma concentrations of 24 ng/mL) or mean plasma levels up to 4 ng/mL are well tolerated and make it worthwhile to further explore the analgesic or antiemetic properties.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18635703 |
3 μg/kg single, intravenous dose: 3 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ORG-28611 blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
Chinese Hamster Ovary (CHO) cells expressing the human CB1 receptor were used for activity evaluation. Cells were suspended in phenol red / serum free DMEM / F-12 nut mix containing penicillin / streptomycin (50U/50 ¬g/ml) and fungizone (1 ¬g/ml) and seeded into 96 well plates at a density of 3 x 10^4 cells per well (100 ¬l final volume). Cells were incubated overnight (approx. 18 hours at 37°C, 5% CO2/95% air) prior to assay. The test compound (10mM solution in DMSO) was diluted in F12 Nut Mix to give a range of stock solutions from 0.11 mM to 0.11 nM. The stock solutions (10mkl) were added directly to the relevant wells. The plates were incubated at 37°C for 5 hours to allow agonist-induced expression of the luciferase enzyme. Under subdued light, LucLite substrate (Packard; reconstituted as per manufacturer’s instructions; 100 mkl) was added to each well. Plates were covered with Top Seal and then incubated at room temperature for 5 minutes before counting on the Packard TopCount (single photon counting, 0.01 minute count time, 5 minute count delay).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
72941840
Created by
admin on Mon Mar 31 18:18:54 GMT 2025 , Edited by admin on Mon Mar 31 18:18:54 GMT 2025
|
PRIMARY | |||
|
Q33173304E
Created by
admin on Mon Mar 31 18:18:54 GMT 2025 , Edited by admin on Mon Mar 31 18:18:54 GMT 2025
|
PRIMARY | |||
|
639068-77-2
Created by
admin on Mon Mar 31 18:18:54 GMT 2025 , Edited by admin on Mon Mar 31 18:18:54 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
